68 phenotypes from 3 alleles in 4 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Cpefat/Cpefat BKSChpLt.HRS-Cpefat/J	abnormal hormone level	J:80698
	abnormal hypothalamus secretion	J:80698
	abnormal pancreatic beta cell morphology	J:24436
	abnormal percent body fat/body weight	J:10872
	decreased circulating adrenocorticotropin level	J:40372
	decreased circulating gastrin level	J:52393
	decreased digestive secretion	J:52393
	degranulated pancreatic beta cells	J:10872
	hyperglycemia	J:10872
	impaired adaptive thermogenesis	J:80698
	increased circulating cholesterol level	J:18161, J:19043
	increased circulating growth hormone level	J:40372
	increased circulating HDL cholesterol level	J:18161, J:19043
	increased circulating insulin level	J:10872, J:24436
	increased circulating LDL cholesterol level	J:19043
	increased circulating pituitary hormone level	J:38227, J:40372
	increased circulating triglyceride level	J:19043
	increased circulating triiodothyronine level	J:80698
	increased circulating VLDL cholesterol level	J:19043
	increased growth hormone level	J:40372
	increased pituitary hormone level	J:40372
	infertility	J:10872
	obese	J:10872
	pancreatic islet hyperplasia	J:10872
Cpefat/Cpefat involves: HRS/J	abnormal pancreatic beta cell morphology	J:10872
	degranulated pancreatic beta cells	J:13651
	hyperglycemia	J:10872
	hypoglycemia	J:13651
	increased circulating insulin level	J:10872, J:13651
	increased pancreatic islet number	J:13651
	increased total body fat amount	J:10872
	infertility	J:10872
	obese	J:10872, J:13651
	pancreatic islet hyperplasia	J:10872
Cpetm1b(EUCOMM)Hmgu/Cpetm1b(EUCOMM)Hmgu C57BL/6N-Cpetm1b(EUCOMM)Hmgu/Ieg	abnormal behavior	J:211773
	abnormal locomotor behavior	J:211773
	aorta stenosis	J:211773
	decreased body length	J:211773
	decreased circulating chloride level	J:211773
	decreased exploration in new environment	J:211773
	decreased food intake	J:211773
	decreased grip strength	J:211773
	decreased locomotor activity	J:211773
	decreased vertical activity	J:211773
	hyperactivity	J:211773
	impaired glucose tolerance	J:211773
	increased circulating alanine transaminase level	J:211773
	increased circulating alkaline phosphatase level	J:211773
	increased circulating aspartate transaminase level	J:211773
	increased circulating calcium level	J:211773
	increased circulating glucose level	J:211773
	increased fasting circulating glucose level	J:211773
	increased hematocrit	J:211773
	increased leukocyte cell number	J:211773
	increased mean corpuscular volume	J:211773
	increased startle reflex	J:211773
	increased thigmotaxis	J:211773
	male infertility	J:211773
Cpetm1Yplo/Cpetm1Yplo involves: 129S1/Sv * C57BL/6	abnormal energy expenditure	J:95741
	abnormal gait	J:95741
	abnormal glucose homeostasis	J:95741
	abnormal hypothalamus secretion	J:95741
	abnormal motor capabilities/coordination/movement	J:95741
	abnormal motor coordination/balance	J:95741
	abnormal muscle physiology	J:95741
	abnormal physical strength	J:95741
	abnormal placing response	J:95741
	decreased grip strength	J:95741
	decreased locomotor activity	J:95741
	decreased vertical activity	J:95741
	hyporesponsive to tactile stimuli	J:95741
	impaired glucose tolerance	J:95741
	increased body length	J:95741
	increased circulating glucose level	J:95741
	increased circulating insulin level	J:95741
	increased circulating leptin level	J:95741
	increased respiratory quotient	J:95741
	increased total body fat amount	J:95741
	insulin resistance	J:95741
	lethargy	J:95741
	obese	J:95741
	polyphagia	J:95741
	reduced fertility	J:95741
	tremors	J:95741